These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28062705)

  • 1. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
    Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
    Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
    Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
    Wang K; Baldwin GS; Nikfarjam M; He H
    Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
    Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
    Mohammad RM; Li Y; Muqbil I; Aboukameel A; Senapedis W; Baloglu E; Landesman Y; Philip PA; Azmi AS
    Small GTPases; 2019 Sep; 10(5):367-377. PubMed ID: 28641032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
    Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
    Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
    Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
    Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
    Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
    Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
    Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
    Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
    Isayev O; Rausch V; Bauer N; Liu L; Fan P; Zhang Y; Gladkich J; Nwaeburu CC; Mattern J; Mollenhauer M; Rückert F; Zach S; Haberkorn U; Gross W; Schönsiegel F; Bazhin AV; Herr I
    Oncotarget; 2014 Jul; 5(13):5177-89. PubMed ID: 25015789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
    Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
    Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
    Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
    Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.